Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LYS006 · 1 trial · 1 indication
Inflammatory facial lesion count included papules, pustules, and nodules. The natural log transformed inflammatory facial lesion count up to Week 12 was analyzed using a Bayesian mixed effect model for repeated measurements (MMRM). Values estimated from the model at Week 12 are presented in the table. Posterior geometric mean and 90% credible intervals in each group are presented.
| Arm | Type | Description |
|---|---|---|
| LYS006 20 mg BID | EXPERIMENTAL | LYS006, 20 mg, orally, twice daily (BID), for 12 weeks |
| LYS006 2 mg BID | EXPERIMENTAL | LYS006, 2 mg, orally, BID, for 12 weeks |
| Placebo BID | PLACEBO_COMPARATOR | Matching placebo, orally, BID, for 12 weeks |
| Name | Type | Description |
|---|---|---|
| LYS006 20 mg | DRUG | LYS006 20 mg, capsules, oral administration, BID, for 12 weeks |
| LYS006 2 mg | DRUG | LYS006 2 mg, capsules, oral administration, BID, for 12 weeks |
| Placebo | DRUG | Matching placebo, capsules, oral administration, BID, for 12 weeks |
Inclusion criteria: * Male and female subjects aged 18 to 45 years of age inclusive, and otherwise in good health as determined by medical history, physical examination, vital signs, ECGs and laboratory tests at screening. * Body weight between 50 and 120 kg, both inclusive, at screening. * Patient...
Top 1 of 2 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 2 | PHASE3 | Ziltivekimab, Semaglutide |
LYS006 is an investigational small molecule drug developed by Novartis AG for the treatment of moderate to severe inflammatory acne. It is a Phase 2 clinical candidate that has been studied in a completed placebo-controlled trial. LYS006 is not yet approved for any indication.
LYS006 is being developed for the treatment of moderate to severe inflammatory acne, a dermatological condition. It has been evaluated in a Phase 2 clinical trial in adult patients with this condition. The drug is investigational and has not received regulatory approval for any use.
LYS006 is developed by Novartis AG, which trades under the ticker symbol NVS. Novartis is the sponsor of the clinical program evaluating LYS006 in inflammatory acne.
LYS006 is in Phase 2 clinical development. A Phase 2 trial in moderate to severe inflammatory acne has been completed. The drug remains investigational and is not approved by the FDA or any other regulatory agency.
LYS006 has been studied in one completed Phase 2 trial, NCT03497897, titled Study to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne. The trial enrolled 66 patients across the United States, Czechia, France, Germany, Hungary, and the Netherlands.